Nomination Committee’s proposal for the Board of Directors prior to Elekta’s Annual General Meeting 2025
STOCKHOLM – The Nomination Committee of Elekta (EKTA-B.ST) proposes that the Annual General Meeting 2025 resolves to reelect Laurent Leksell, Ann Costello, Tomas Eliasson, Jan Kimpen, Wolfgang Reim, Jan Secher, Volker Wetekam and Cecilia Wikström, and to elect Jan De Witte, as Directors of the Board of Directors for the period until the end of the next Annual General Meeting. Furthermore, the Nomination Committee proposes that Laurent Leksell is reelected as the Chairman of the Board of Directors.
Jan De Witte is a seasoned executive with more than 25 years of experience in the global technology and life science industries. As the former CEO for Integra LifeSciences, a U.S.-based global leader in neurosurgery and regenerative technologies, between 2021-2024, and for Belgian Barco, a leading global advanced visualization technology company, between 2016-2021, Jan De Witte will bring relevant and extensive leadership expertise both from an industry as well as a regional perspective. Before taking on CEO roles, he held various global senior-level leadership roles at GE HealthCare, spanning hardware, software and services business segments in medtech and healthtech. Jan De Witte’s career began with foundational roles as senior strategy consultant at McKinsey in Europe, and operations at Procter & Gamble in Belgium. Jan De Witte currently serves as an operating partner at GHO Capital Partners, a European healthcare specialist private equity investor, as well as on the Board of Directors of ResMed, a global company focusing on sleep health. Jan de Witte holds a Bachelor’s and Master of Science degree in electromechanical engineering from the KU Leuven in Belgium and a Master of Business Administration from Harvard Business School. He is a Belgian citizen, resides in Kortrijk, Belgium, and was born in 1964.
The Nomination Committee’s complete proposal will be published in connection with the convening of Elekta’s Annual General Meeting 2025, held on September 4, 2025.
Prior to the Annual General Meeting 2025, the Nomination Committee consists of Laurent Leksell, in his capacity as the Chairman of the Board of Directors of Elekta and representing his own and related parties’ holdings, Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund, Katarina Hammar, appointed by Nordea Funds, Patrik Jönsson, appointed by SEB Funds, and Jesper Bergström, appointed by Handelsbanken Funds. The Chairman of the Nomination Committee is Laurent Leksell.
# # #
For further information, please contact:
Peter Nyquist, Vice President, Head of Investor Relations
Tel: +46 70 575 2906, e-mail: peter.nyquist@elekta.com
Time zone: CEST: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.